Abstract
Among hereditary diseases, the group of motor neuron diseases (MNDs) includes some of the most devastating and rapidly progressive lethal conditions. Although degeneration of motor neurons is common to all of them, the phenotypic spectrum of MNDs is relatively broad and ranges from perinatal conditions like spinal muscular atrophy (SMA) to adult-onset diseases such as amyotrophic lateral sclerosis (ALS). While the understanding of the pathology of the diseases is constantly growing, the development of therapeutic approaches lags behind. In fact, there is no approved therapy for MNDs available at the moment.
Recent findings demonstrated the existence of some patterns that are shared by several MNDs such as transcriptional dysregulation. In addition, conditions like SMA or certain types of Charcot-Marie-Tooth disease provide some defined targets which may be amenable to therapeutic approaches. Consequently, counteracting this dysregulation may be a valuable therapeutic option and ameliorate disease progression in MND patients. The feasibility of such an approach has been proven during the past years by the epigenetic treatment of various neoplastic entities with histone deacetylase inhibitors (HDACi). On these grounds, also epigenetic therapy of MNDs has become a promising option. So far, several HDACi have been tested in vitro and in animal models and some proceeded further and were evaluated in clinical trials. This review will summarize the advances of HDACi in MNDs and will give a perspective where the road will lead us.
Keywords: Amyotrophic lateral sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, HSP1, HDAC inhibitor, valproic acid, SAHA, trichostatin A.
Current Pharmaceutical Design
Title:Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases
Volume: 19 Issue: 28
Author(s): Lutz Garbes, Markus Riessland and Brunhilde Wirth
Affiliation:
Keywords: Amyotrophic lateral sclerosis, spinal muscular atrophy, spinal and bulbar muscular atrophy, HSP1, HDAC inhibitor, valproic acid, SAHA, trichostatin A.
Abstract: Among hereditary diseases, the group of motor neuron diseases (MNDs) includes some of the most devastating and rapidly progressive lethal conditions. Although degeneration of motor neurons is common to all of them, the phenotypic spectrum of MNDs is relatively broad and ranges from perinatal conditions like spinal muscular atrophy (SMA) to adult-onset diseases such as amyotrophic lateral sclerosis (ALS). While the understanding of the pathology of the diseases is constantly growing, the development of therapeutic approaches lags behind. In fact, there is no approved therapy for MNDs available at the moment.
Recent findings demonstrated the existence of some patterns that are shared by several MNDs such as transcriptional dysregulation. In addition, conditions like SMA or certain types of Charcot-Marie-Tooth disease provide some defined targets which may be amenable to therapeutic approaches. Consequently, counteracting this dysregulation may be a valuable therapeutic option and ameliorate disease progression in MND patients. The feasibility of such an approach has been proven during the past years by the epigenetic treatment of various neoplastic entities with histone deacetylase inhibitors (HDACi). On these grounds, also epigenetic therapy of MNDs has become a promising option. So far, several HDACi have been tested in vitro and in animal models and some proceeded further and were evaluated in clinical trials. This review will summarize the advances of HDACi in MNDs and will give a perspective where the road will lead us.
Export Options
About this article
Cite this article as:
Garbes Lutz, Riessland Markus and Wirth Brunhilde, Histone Acetylation as a Potential Therapeutic Target in Motor Neuron Degenerative Diseases, Current Pharmaceutical Design 2013; 19 (28) . https://dx.doi.org/10.2174/13816128113199990356
DOI https://dx.doi.org/10.2174/13816128113199990356 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)
Current Topics in Medicinal Chemistry The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
Current Neuropharmacology Antiepileptic Drugs for Preventing Seizures in Patients with Chronic Subdural Hematoma
Current Pharmaceutical Design Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research Anticholinergic Effects of Oral Antipsychotic Drugs of Typicals Versus Atypicals Over Medium- and Long-Term: Systematic Review and Meta-Analysis
Current Medicinal Chemistry Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets Natural Products Based Ayurvedic Formulations: Chemical Cons tituents and Treatment in Neurodegenerative Disordersǂ
Mini-Reviews in Organic Chemistry Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design Comparative Study of the Effects Exerted by N-Valproyl-L-Phenylalanine and N-valproyl-L-tryptophan on CA1 Hippocampal Epileptiform Activity in Rat
Current Pharmaceutical Design Synthesis and Anticonvulsant Activity of Some Novel Semicarbazone Containing Benzoxazole: Pharmacophore Model Study
Current Bioactive Compounds Medication-precipitated Seizure in Psychiatric Patients: Typical vs. Atypical Antipsychotics
Current Psychopharmacology Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity
Current Neuropharmacology Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV Infection
Current Pharmacogenomics and Personalized Medicine Histamine H<sub>4</sub> Receptor Antagonists: A New Approach for Tinnitus Treatment?
Recent Patents on CNS Drug Discovery (Discontinued) The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology Editorial [Hot Topic: Ion Channels: Applications in Ion Channel Drug Discovery(Guest Editor: Douglas S. Krafte)]
Combinatorial Chemistry & High Throughput Screening